Phase II study of everolimus in children and adults with neurofibromatosis type 2 and progressive vestibular schwannomas

BACKGROUND: Activation of the mammalian target of rapamycin (mTOR) signaling pathway is thought to be a key driver of tumor growth in Merlin (NF2)-deficient tumors. Everolimus is an oral inhibitor of mTOR complex 1 (mTORC1) with antitumor activity in a variety of cancers. METHODS: We conducted a sin...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Karajannis, Matthias A., Legault, Geneviève, Hagiwara, Mari, Giancotti, Filippo G., Filatov, Alexander, Derman, Anna, Hochman, Tsivia, Goldberg, Judith D., Vega, Emilio, Wisoff, Jeffrey H., Golfinos, John G., Merkelson, Amanda, Roland, J. Thomas, Allen, Jeffrey C.
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2014
Assuntos:
Clinical Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3895376/
https://ncbi.nlm.nih.gov/pubmed/24311643
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/not150
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados